The epigenetic modifier gene mutations, ASXL1, DNMT3A and TET2 (ADT) recurrently occur in AML/MDS and result in a dismal prognosis11, 12 with a low rate of remission and short progression‐free survival.13, 14, 15. The gene discussed is ASXL1; the disease is acute myeloid leukemia.